Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Men with idiopathic hypogonadotropic hypogonadism (IHH, Kallmann Syndrome) may have small testicular size, low testosterone levels, no history of puberty, and infertility. These men lack a hormone called gonadotropin releasing hormone (GnRH) that stimulates the development and maturation of the testes. This study will investigate the impact of hormonal treatments on men with IHH. The goal of hormonal therapy is to maximize the potential fertility in these individuals.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypogonadism Kallmann Syndrome |
Procedure: Testicular biopsy Drug: gonadotropin releasing hormone (GnRH) Drug: follicle stimulating hormone (FSH) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Role of FSH in Human Gonadal Development |
- LH [ Time Frame: weekly & monthly ] [ Designated as safety issue: No ]
- FSH [ Time Frame: weekly & monthly ] [ Designated as safety issue: No ]
- testosterone [ Time Frame: weekly & monthly ] [ Designated as safety issue: No ]
- Inhibin B [ Time Frame: weekly & monthly ] [ Designated as safety issue: No ]
- testicular size (volume) [ Time Frame: monthly ] [ Designated as safety issue: No ]
- sperm count [ Time Frame: monthly ] [ Designated as safety issue: No ]
- Fertility [ Time Frame: 24 months ] [ Designated as safety issue: No ]
| Enrollment: | 14 |
| Study Start Date: | April 2001 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
-
Procedure: Testicular biopsy
Though steroid output of the testes is minimal during childhood, important changes take place that impact spermatogenic potential. Specifically, the number of Sertoli cells increases until testosterone secretion rises during puberty. In animal models, the proliferation of Sertoli cells appears to be regulated by follicle stimulating hormone (FSH) even though FSH levels in childhood are relatively low. At puberty, the number of Sertoli cells becomes fixed; however, the existing cell population then undergoes functional maturation. This switch from proliferation to maturation of Sertoli cells appears to result from rising levels of intratesticular testosterone.
FSH deficiency during testicular development results in decreased numbers of Sertoli cells, even if physiologic hormonal replacement therapy is introduced in adolescence or adulthood. The number of mature Sertoli cells appears to correlate with testicular size, sperm count, and future fertility. An improved understanding of the specific roles of FSH, luteinizing hormone (LH), and testosterone in testicular development may have direct clinical applications in the treatment of male infertility. This study will define the role of FSH in stimulating Sertoli cell proliferation in the human male.
Patients in this study will be randomized to receive either FSH and GnRH (Group 1) or GnRH alone (Group 2). Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will receive the same regimen of exogenous GnRH for 18 months without prior FSH administration.
All patients will undergo an initial assessment that includes an overnight 12-hour frequent blood sampling study, testicular ultrasound, and testicular biopsy. Patients will be followed through monthly study visits with blood tests and seminal fluid analysis. Patients will also have serial testicular ultrasounds to measure testicular growth. Patients in Group 1 will also have a second frequent blood sampling to measure LH, FSH, and testosterone and to confirm the absence of LH pulses.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- no history of spontaneous puberty
- clinical hypogonadism
- infantile testes (< 3 ml)
- no reproductive hormone therapy except testosterone
- Complete absence of normal LH pulses during 12-hour baseline frequent blood sampling and serum testosterone < 100 ng/dl
- Normal testing of the anterior pituitary gland
- Negative MRI of the hypothalamic-pituitary area
Exclusion Criteria
- Prior therapy with gonadotropins (FSH, hCG, or GnRH)
Contacts and Locations| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | William F Crowley, Jr., MD | Massachusetts General Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | William Crowley, Principle Investigator, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| ClinicalTrials.gov Identifier: | NCT00064987 History of Changes |
| Other Study ID Numbers: | U54HD028138-457 |
| Study First Received: | July 16, 2003 |
| Last Updated: | April 17, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
|
Male reproduction hormones Hypogonadotropic hypogonadism FSH LH GnRH |
Additional relevant MeSH terms:
|
Hypogonadism Kallmann Syndrome Gonadal Disorders Endocrine System Diseases 46, XY Disorders of Sex Development Disorders of Sex Development Urogenital Abnormalities |
Congenital Abnormalities Genetic Diseases, Inborn Hormones Follicle Stimulating Hormone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013